A six-year review of DETROL LA data found significant symptom reduction for overactive bladder patients, including improved quality of life measures. The medication was associated with a low frequency of side effects, particularly dry mouth.
A prospective study found that combining DETROL LA with standard treatment for enlarged prostate results in improved symptoms of overactive bladder, with 73% of patients experiencing relief. The most common side effects were dry mouth and dizziness.
A double-blind, randomized trial found that first-line treatment with DETROL(R) LA significantly reduced urge incontinence episodes and improved bladder condition in women with mixed incontinence. The study also showed a higher proportion of patients treated with DETROL(R) LA reported treatment benefits.
A new clinical trial demonstrates that treating migraine with Relpax during mild pain provides greater efficacy than waiting for pain to become more severe. Patients who treated early experienced significantly higher two-hour pain-free rates compared to those who waited.